Evidence map›Paper›PMID 42198318›Full record

ArticlePharmaceutics2026

Development and Evaluation of "a PEGylated Anti-Tau ScFv for SPECT Imaging" in a Rat Model of Traumatic Brain Injury.

Esmat Sajjadi, Ehsan Sharif-Paghaleh, Mohammad Akrami, Koorosh Shahpasand, Ismaeil Haririan, Samane Maghsoudian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esmat SajjadiDepartment of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, 16Azar Street, Tehran 1417614411, Iran.
Ehsan Sharif-PaghalehDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1461884513, Iran.ORCID 0000-0002-0229-2524
Mohammad AkramiDepartment of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, 16Azar Street, Tehran 1417614411, Iran.ORCID 0000-0002-4706-9385
Koorosh ShahpasandDepartment of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN 55414, USA.
Ismaeil HaririanDepartment of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, 16Azar Street, Tehran 1417614411, Iran.
Samane MaghsoudianDepartment of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran.

Funding

Tehran University of Medical Sciences 46426
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

99m Tc labeled scFvneuroimagingPEGylationTau-targeted SPECT imagingTBI

Identifiers

PMID42198318
PMCPMC13210521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.